Advertisement

Zeitschrift für Epileptologie

, Volume 32, Issue 1, pp 12–20 | Cite as

Narkolepsie – mit Beachtung der Kataplexie als Differenzialdiagnose epileptischer Anfälle

  • Ramin KhatamiEmail author
  • Ulf KallweitEmail author
Leitthema
  • 13 Downloads

Zusammenfassung

Die Narkolepsie gilt als Modellerkrankung für das Verständnis der Pathophysiologie von Schlaf-Wach-Regulation. Zahlreiche Entdeckungen zur Narkolepsie – wie die des Orexinsystems oder die Rolle des Immunsystems – haben Einfluss auf die gesamte Schlafmedizin.

Schlüsselwörter

Kataplexie Orexin/Hypocretin Autoimmungenese Schlaf-Wach-Regulation Exzessive Tagesschläfrigkeit 

Narcolepsy—considering cataplexy as a differential diagnosis of epileptic seizures

Abstract

The pathophysiology of narcolepsy provides valuable insights into mechanisms of sleep-wake regulation in general. Recent data and discoveries, such as the orexin-hypocretin system, the role of the immune system and new drugs for pharmacological treatment have a profound impact on multiple sleep-related aspects in health and disease.

Keywords

Cataplexy Orexin/hypocretin Autoimmunity Sleep-wake regulation Excessive daytime sleepiness 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

R. Khatami erhielt Honorare für Referenten- und Beratertätigkeit von UCB Pharma. U. Kallweit erhielt Honorare für Referenten- bzw. Beratertätigkeit von den Firmen AOP Orphan, Bioprojet Pharma, Harmony Biosciences, UCB Pharma, Jazz Pharma.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    American Academy of Sleep Medicine (2014) The International Classification of Sleep Disorders: 3rd ed.: Diagnostic and Coding Manual. Westchester, IllinoisGoogle Scholar
  2. 2.
    Andlauer O, Moore H, Hong S, Dauvilliers Y, Kanbayashi Y, Nishino S, Han F, Silber MH, Rico T, Einen M, Kornum BR, Jennum P, Knudsen S, Nevsimalova S, Poli F, Plazzi G, Mignot E (2012) Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep 35:1247–1255PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Aran A, Lin L, Nevsimalova S, Plazzi G, Hong SC, Weiner K, Zeitzer J, Mignot E (2009) Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 32:979–983PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Bassetti CL, Baumann CR, Dauvilliers Y, Croyal M, Robert P, Schwartz JC (2010) Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin. J Sleep Res 19:620–623PubMedCrossRefGoogle Scholar
  5. 5.
    Bergman P, Adori C, Vas S, Kai-Larsen Y, Sarkanen T, Cederlund A, Agerberth B, Julkunen I, Horvath B, Kostyalik D, Kalmár L, Bagdy G, Huutoniemi A, Partinen M, Hökfelt T (2014) Narcolepsy patients have antibodies that stain distinct cell populations in rat brain and influence sleep patterns. Proc Natl Acad Sci USA 111:3735–3744CrossRefGoogle Scholar
  6. 6.
    Bernard-Valnet R, Yshii L, Quériault C, Nguyen X, Arthaud S, Rodrigues M, Canivet A, Morel A, Matthys A, Bauer J, Pignolet B, Dauvilliers Y, Peyron C, Liblau R (2016) CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice. Proc Natl Acad Sci U S A 113:10956–10961PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Broughton R, Valley V, Aguirre M, Roberts J, Suwalski W, Dunham W (1986) Excessive daytime sleepiness and the pathophysiology of narcolepsy-cataplexy: a laboratory perspective. Sleep 9:205–215PubMedCrossRefGoogle Scholar
  8. 8.
    Cvetkovic-Lopes V, Bayer L, Dorsaz S et al (2010) Elevated Tribbles homolog 2‑specific antibody levels in narcolepsy patients. J Clin Invest.  https://doi.org/10.1172/jci41366 PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, Lehert P, Ding CL, Lecomte JM, Schwartz JC, HARMONY I study group (2013a) Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol 12:1068–1075PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Dauvilliers Y, Bauer J, Rigau V, Lalloyer N, Labauge P, Carlander B, Liblau R, Peyron C, Lassmann H (2013b) Hypothalamic immunopathology in anti-Ma-associated diencephalitis with narcolepsy-cataplexy. JAMA Neurol 70:1305–1310PubMedGoogle Scholar
  11. 11.
    Dauvilliers Y, Delallee N, Jaussent I, Scholz S, Bayard S, Croyal M, Schwartz JC, Robert P (2012) Normal cerebrospinal fluid histamine and tele-methylhistamine levels in hypersomnia conditions. Sleep 35:1359–1366PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Dauvilliers Y, Montplaisir J, Molinari N (2001) Age at onset of narcolepsy in two large populations of patients in France and Quebec. Baillieres Clin Neurol 57:2029–2033Google Scholar
  13. 13.
    Degn M, Dauvilliers Y, Dreisig K et al (2017) Rare missense mutations in P2RY11 in narcolepsy with cataplexy. Brain 140:1657–1668PubMedCrossRefGoogle Scholar
  14. 14.
    Duchowny MS, Deray MJ, Papazian O (1985) Narcolepsy-cataplexy and gelastic atonic seizures. Baillieres Clin Neurol 35:775–776Google Scholar
  15. 15.
    Faraco J, Lin L, Kornum BR et al (2013) ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet 9:e1003270PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Gelb M, Guilleminault C, Kraemer H, Lin S, Moon S, Dement WC, Mignot E (1994) Stability of cataplexy over several months – information for the design of therapeutic trials. Sleep 17:265–273PubMedCrossRefGoogle Scholar
  17. 17.
    Guo L, Ambati A, Lin L, Bonvalet M, Partinen M, Ji X, Maecker HT, Mignot E (2018) Autoimmunity to hypocretin and molecular mimicry to flu antigens in type 1 narcolepsy. bioRxivGoogle Scholar
  18. 18.
    Haggmark-Manberg A, Zandian A, Forsström B et al (2016) Autoantibody targets in vaccine-associated narcolepsy. Autoimmunity 49:421–433PubMedCrossRefGoogle Scholar
  19. 19.
    Hallmayer J, Faraco J, Lin L, Hesselson S, Winkelmann J, Kawashima M, Mayer G, Plazzi G, Nevsimalova S, Bourgin P, Hong SS, Honda Y, Honda M, Hogl B, Longstreth WT Jr., Montplaisir J, Kemlink D, Einen M, Chen J, Musone SL, Akana M, Miyagawa T, Duan J, Desautels A, Erhardt C, Hesla PE, Poli F, Frauscher B, Jeong JH, Lee SP, Ton TG, Kvale M, Kolesar L, Dobrovolna M, Nepom GT, Salomon D, Wichmann HE, Rouleau GA, Gieger C, Levinson DF, Gejman PV, Meitinger T, Young T, Peppard P, Tokunaga K, Kwok PY, Risch N, Mignot E (2009) Narcolepsy is strongly associated with the T‑cell receptor alpha locus. Nat Genet 41:708–711PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Han F, Pin L, Warby SC (2011) Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 70:410–417PubMedCrossRefGoogle Scholar
  21. 21.
    van der Heide A, Hegeman-Kleinn IM, Peeters E et al (2015) Immunohistochemical screening for antibodies in recent onset type 1 narcolepsy and after H1N1 vaccination. J Neuroimmunol 283:58–62PubMedCrossRefGoogle Scholar
  22. 22.
    Heier MS, Evsiukova T, Wilson J, Abdelnoor M, Hublin C, Ervik S (2009) Prevalence of narcolepsy with cataplexy in Norway. Acta Neurol Scand 120:276–280PubMedCrossRefGoogle Scholar
  23. 23.
    De la Herran-Arita AK, Kornum BR, Mahlios J, Jiang W, Lin L, Hou T, Macaubas C, Einen M, Plazzi G, Crowe C, Newell EW, Davis MM, Mellins ED, Mignot E (2013) CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med 5:216ra176PubMedCrossRefGoogle Scholar
  24. 24.
    De la Herrán-Arita AK, Kornum BR, Mahlios J, Jiang W, Lin L, Hou T, Macaubas C, Einen M, Plazzi G, Crowe C, Newell EW, Davis MM, Mellins ED, Mignot E (2014) Retraction of the research article: „CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy“. Sci Transl Med 6:247rt241Google Scholar
  25. 25.
    Hidalgo H, Kallweit U, Mathis J, Bassetti CL (2016) Post tick-borne encephalitis virus vaccination narcolepsy with cataplexy. Sleep 39:1811–1814PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Hishikawa Y, Kaneko Z (1965) Electroencephalographic study on narcolepsy. Electroencephalogr Clin Neurophysiol 18:249–259PubMedCrossRefGoogle Scholar
  27. 27.
    Hor H, Bartesaghi L, Kutalik Z, Vicario JL, de Andres C, Pfister C, Lammers GJ, Guex N, Chrast R, Tafti M, Peraita-Adrados R (2011) A missense mutation in myelin oligodendrocyte glycoprotein as a cause of familial narcolepsy with cataplexy. Am J Hum Genet 89:474–479PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Hor H, Kutalik Z, Dauvilliers Y, Valsesia A, Lammers GJ, Donjacour CE, Iranzo A, Santamaria J, Peraita Adrados R, Vicario JL, Overeem S, Arnulf I, Theodorou I, Jennum P, Knudsen S, Bassetti C, Mathis J, Lecendreux M, Mayer G, Geisler P, Beneto A, Petit B, Pfister C, Burki JV, Didelot G, Billiard M, Ercilla G, Verduijn W, Claas FH, Vollenweider P, Waeber G, Waterworth DM, Mooser V, Heinzer R, Beckmann JS, Bergmann S, Tafti M (2010) Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet 42:786–789PubMedCrossRefGoogle Scholar
  29. 29.
    Huang ZL, Qu WM, Li WD, Mochizuki T, Eguchi N, Watanabe T, Urade Y, Hayaishi O (2001) Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci USA 98:9965–9970PubMedCrossRefGoogle Scholar
  30. 30.
    Hungs M, Lin L, Okun M, Mignot E (2001) Polymorphisms in the vicinity of the hypocretin/orexin are not associated with human narcolepsy. Baillieres Clin Neurol 57:1893–1895Google Scholar
  31. 31.
    Jacome DE, Risko M (1984) Pseudocataplexy: gelastic-atonic seizures. Baillieres Clin Neurol 34:1381–1383Google Scholar
  32. 32.
    Jennum P, Ibsen R, Petersen ER, Knudsen S, Kjellberg J (2012) Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners. Sleep Med 13:1086–1093PubMedCrossRefGoogle Scholar
  33. 33.
    John J, Thannickal TC, McGregaor R et al (2013) Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. Ann Neurol 74:786–793PubMedCrossRefGoogle Scholar
  34. 34.
    Juji T, Matsuki L, Tokunaga K, Naohara K, Honda Y (1988) Narcolepsy and HLA in the Japanese. Ann N Y Acad Sci 540:106–114PubMedCrossRefGoogle Scholar
  35. 35.
    Kawashima M, Lin L, Tanaka S, Jennum P, Knudsen S, Nevsimalova S, Plazzi G, Mignot E (2010) Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep 33:869–874PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Khatami R, Birkmann S, Bassetti CL (2007) Amgydala dysfunction in narcolepsy-cataplexy. J Sleep Res.  https://doi.org/10.1111/j.1365-2869.2007.00587.x PubMedCrossRefGoogle Scholar
  37. 37.
    Khatami R, Luca G, Baumann CR, Bassetti CL, Bruni O, Canellas F, Dauvilliers Y, Del Rio-Villegas R, Feketeova E, Ferri R, Geisler P, Hogl B, Jennum P, Kornum BR, Lecendreux M, Martins-da-Silva A, Mathis J, Mayer G, Paiva T, Partinen M, Peraita-Adrados R, Plazzi G, Santamaria J, Sonka K, Riha R, Tafti M, Wierzbicka A, Young P, Lammers GJ, Overeem S, European Narcolepsy Network (2016) The European Narcolepsy Network (EU-NN) database. J Sleep Res 25:356–364PubMedCrossRefGoogle Scholar
  38. 38.
    Khatami R, Maret S, Werth E, Retey J, Schmid D, Maly F, Tafti M, Bassetti CL (2004) Monozygotic twins concordant for narcolepsy-cataplexy without any detectable abnormality in the hypocretin (orexin) pathway. Lancet 363:1199–1200PubMedCrossRefGoogle Scholar
  39. 39.
    Kornum BR, Kawashima M, Faraco J, Lin L, Rico TJ, Hesselson S, Axtell RC, Kuipers H, Weiner K, Hamacher A, Kassack MU, Han F, Knudsen S, Li J, Dong X, Winkelmann J, Plazzi G, Nevsimalova S, Hong SC, Honda Y, Honda M, Hogl B, Ton TG, Montplaisir J, Bourgin P, Kemlink D, Huang YS, Warby S, Einen M, Eshragh JL, Miyagawa T, Desautels A, Ruppert E, Hesla PE, Poli F, Pizza F, Frauscher B, Jeong JH, Lee SP, Strohl KP, Longstreth WT Jr., Kvale M, Dobrovolna M, Ohayon MM, Nepom GT, Wichmann HE, Rouleau GA, Gieger C, Levinson DF, Gejman PV, Meitinger T, Peppard P, Young T, Jennum P, Steinman L, Tokunaga K, Kwok PY, Risch N, Hallmayer J, Mignot E (2011) Common variants in P2RY11 are associated with narcolepsy. Nat Genet 43:66–71PubMedCrossRefGoogle Scholar
  40. 40.
    Latorre D, Kallweit U, Armentani E, Foglierini M, Mele F, Cassotta A, Jovic S, Jarrossay D, Mathis J, Zellini F, Becher B, Lanzavecchia A, Khatami R, Manconi M, Tafti M, Bassetti CL, Sallusto F (2018) T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature 562:63–68PubMedCrossRefGoogle Scholar
  41. 41.
    de Lecea L, Kilduff TS, Peyron C (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 95:322–327PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    McLeod S, Ferrie C, Zuberi SM (2005) Symptoms of narcolepsy in children misinterpreted as epilepsy. Epileptic Disord 7:13–17Google Scholar
  43. 43.
    Mensen A, Poryazova R, Huegli G, Baumann C, Schwartz S, Khatami R (2015) The roles of dopamine and hypocretin in reward: a electroencephalographic study. PLoS ONE 10:15CrossRefGoogle Scholar
  44. 44.
    Mignot E (1998) Genetic and familial aspects of narcolepsy. Baillieres Clin Neurol 50:S16–S22Google Scholar
  45. 45.
    Ohayon M, Priest RG, Zulley J, Smirne S, Paiva T (2002) Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Baillieres Clin Neurol 58:1826–1833Google Scholar
  46. 46.
    Olafsdottir BR, Rye DB, Scammell TE, Matheson JK, Stefansson K, Gulcher JR (2001) Polymorphisms in hypocretin/orexin pathway genes and narcolepsy. Baillieres Clin Neurol 57:1896–1899Google Scholar
  47. 47.
    Ollila HM, Ravel JM, Han F, Faraco J, Lin L, Zheng X, Plazzi G, Dauvilliers Y, Pizza F, Hong SC, Jennum P, Knudsen S, Kornum BR, Dong XS, Yan H, Hong H, Coquillard C, Mahlios J, Jolanki O, Einen M, Arnulf I, Hogl B, Frauscher B, Crowe C, Partinen M, Huang YS, Bourgin P, Vaarala O, Desautels A, Montplaisir J, Mack SJ, Mindrinos M, Fernandez-Vina M, Mignot E (2015) HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy. Am J Hum Genet 96:136–146PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Overeem S, van Nues SJ, van der Zande WL, Donjacour CE, van Mierlo P, Lammers GJ (2011) The clinical features of cataplexy: a questionnaire study in narcolepsy patients with and without hypocretin-1 deficiency. Sleep Med 12:12–18PubMedCrossRefGoogle Scholar
  49. 49.
    Partinen M, Kornum BR, Plazzi G, et al. (2014) Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol 13:600–613PubMedCrossRefGoogle Scholar
  50. 50.
    Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, Hublin C, Linna M, Olsen P, Nokelainen P, Alen R, Wallden T, Espo M, Rusanen H, Olme J, Satila H, Arikka H, Kaipainen P, Julkunen I, Kirjavainen T (2012) Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 7:e33723PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991–997PubMedCrossRefGoogle Scholar
  52. 52.
    Plazzi G, Pizza F, Palaia V, Franceschini C, Poli F, Moghadam KK, Cortelli P, Nobili L, Bruni O, Dauvilliers Y, Lin L, Edwards MJ, Mignot E, Bhatia KP (2011) Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain 134:3480–3492CrossRefGoogle Scholar
  53. 53.
    Ponz A, Khatami R, Poryazova R, Werth E, Boesiger P, Bassetti CL, Schwartz S (2010) Abnormal activity in reward brain circuits in human narcolepsy with cataplexy. Ann Neurol 67:190–200PubMedCrossRefGoogle Scholar
  54. 54.
    Poryazova R, Siccoli M, Werth E, Bassetti CL (2005) Unusually prolonged rebound cataplexy after withdrawal of fluoxetine. Baillieres Clin Neurol 65:967–968Google Scholar
  55. 55.
    Rocca FL, Pizza F, Ricci E, Plazzi G (2015) Narcolepsy during childhood: an update. Neuropediatrics 46:181–198PubMedCrossRefGoogle Scholar
  56. 56.
    Saariaho AH, Vuorela A, Freitag TL et al (2015) Autoantibodies against ganglioside GM3 are associated with narcolepsy-cataplexy developing after Pandemrix vaccination against 2009 pandemic H1N1 type influenza virus. J Autoimmun 63:68–75PubMedCrossRefGoogle Scholar
  57. 57.
    Sakurai T, Amemiya A, Ishii M (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573–585PubMedCrossRefGoogle Scholar
  58. 58.
    Schwartz JC (2011) The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol 163:713–721PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Sturzenegger C, Bassetti CL (2004) The clinical spectrum of narcolepsy with cataplexy: a reappraisal. J Sleep Res 13:395–406PubMedCrossRefGoogle Scholar
  60. 60.
    Szakacs Z, Dauvilliers Y, Mikhaylov V, Poverennova I, Krylov S, Jankovic S, Sonka K, Lehert P, Lecomte I, Lecomte JM, Schwartz JC, HARMONY-CTP study group (2017) Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16:200–207PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Tafti M, Hor H, Dauvilliers Y, et al. (2014) DQB1 Locus Alone Explains Most of the Risk and Protection in Narcolepsy with cataplexy in Europe. Sleep 37:19–25PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Tafti M, Lammers GJ, Dauvilliers Y, Overeem S, Mayer G, Nowak J, Pfister C, Dubois V, Eliaou JF, Eberhard HP, Liblau R, Wierzbicka A, Geisler P, Bassetti CL, Mathis J, Lecendreux M, Khatami R, Heinzer R, Haba-Rubio J, Feketeova E, Baumann CR, Kutalik Z, Tiercy JM (2016) Narcolepsy-associated HLA class I alleles implicate cell-mediated cytotoxicity. Sleep 39:581–587PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Thebault S, Waters S, Snape MD et al (2015) Neuronal antibodies in children with or without narcolepsy following H1N1-AS03 vaccination. PLoS ONE 10:e129555PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Toyoda H, Tanaka S, Miyagawa T, Honda Y, Tokunaga K, Honda M (2010) Anti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy. Sleep 33:875–878PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    U.S. Xyrem Multicenter Study Group (2004) Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 5:119–123CrossRefGoogle Scholar
  66. 66.
    Valko PO, Gavrilov YV, Yamamoto M, Reddy H, Haybaeck J, Mignot E, Baumann CR, Scammell TE (2013) Increase of histaminergic tuberomammillary neurons in narcolepsy. Ann Neurol 74:794–804PubMedCrossRefGoogle Scholar
  67. 67.
    Yoss RE, Daly DD (1960) Narcolepsy. Med Clin North Am 44:955–968CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Zentrum für Schlafmedizin, Schlafforschung und EpileptologieKlinik Barmelweid AGBarmelweidSchweiz
  2. 2.Neurologische Klinik für NeurologieInselspital, Universitätsspital Bern, Universität BernBernSchweiz
  3. 3.Zentrum für Narkolepsie, Institut für ImmunologieUniversität Witten/HerdeckeWittenDeutschland

Personalised recommendations